Loading…
Cartesian Therapeutics, Inc. is projected to rise to $7.03 by 2027, a +1% move from its current price of $6.93. RNAC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.59 | $6.93 | $7.29 | +0.02% |
| May 30 | $6.46 | $6.93 | $7.44 | +0.04% |
| May 31 | $6.36 | $6.93 | $7.56 | +0.05% |
| Jun 1 | $6.27 | $6.93 | $7.66 | +0.07% |
| Jun 2 | $6.20 | $6.94 | $7.76 | +0.09% |
| Jun 3 | $6.14 | $6.94 | $7.84 | +0.11% |
| Jun 4 | $6.08 | $6.94 | $7.92 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.08 | $6.94 | $7.92 | +0.12% |
| Week 2 | $5.76 | $6.95 | $8.38 | +0.25% |
| Week 3 | $5.53 | $6.96 | $8.75 | +0.37% |
| Week 4 | $5.34 | $6.96 | $9.08 | +0.50% |
| Week 5 | $5.19 | $6.97 | $9.37 | +0.62% |
| Week 6 | $5.05 | $6.98 | $9.66 | +0.74% |
| Week 7 | $4.92 | $6.99 | $9.92 | +0.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company that provides mRNA cell therapies for the treatment of autoimmune diseases. Its lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell directed against BCMA, in Phase 2b clinical trials for autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, with rare pediatric disease designation for juvenile dermatomyositis.
It is also developing Descartes-15, which is in Phase 1 trials, an autologous BCMA-directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
These facts establish Cartesian Therapeutics as a biotechnology company focused on mRNA CAR-T therapies for autoimmune diseases and related oncology indications, with multiple product candidates at different stages of clinical development.
Cartesian Therapeutics, Inc. trades under the symbol RNAC and has a current price of $6.75 with a market cap of $198.33M, ranking 3853 by market capitalization. The stock’s current positioning sits within a narrow trading context given a 30-day range that spans from $4.86 to $9.38, and it shows a bearish overall technical tone despite a mid-range RSI reading.
The forecasted path for RNAC spans a multi-year horizon, with year-by-year projections showing variability but an overall upside trajectory. The average price in 2026 is $6.75, rising through the years to a 2050 average of $19.75, with notable peak upside in later years. Return-on-investment figures advance from positive in several years to high-double-digit levels in the 2040s and 2050s, underscoring potential long-run upside amid rising bullish sentiment in the later horizon.
A major floor 35.1% below — a decisive break under it would weaken the trend.
The nearest floor, 13.6% below — buyers have tended to step in here.
The nearest ceiling, 25.5% above — a clean break opens room to run.
A major ceiling 43.1% above — clearing it would confirm fresh momentum.
Key RNAC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RNAC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.67 | Buy | $6.77 | Buy |
| MA 10 | $7.04 | Sell | $6.96 | Sell |
| MA 20 | $7.30 | Sell | $7.09 | Sell |
| MA 50 | $6.79 | Buy | $7.04 | Sell |
| MA 100 | $7.04 | Sell | $7.25 | Sell |
| MA 200 | $7.97 | Sell | $8.39 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.34 | Neutral |
| Stoch RSI (14) | 32.94 | Neutral |
| CCI (20) | -30.25 | Neutral |
| Williams %R (14) | -67.82 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -19.88 | Sell |
| Bollinger %B (20,2) | 0.40 | Neutral |
| Stochastic %K (14) | 32.18 | Neutral |
| TRIX (15) | 0.26 | Buy |
| Awesome (5,34) | -0.34 | Sell |
| Ultimate (7,14,28) | 41.69 | Neutral |
| Momentum (10) | -1.77 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 6.58 | Buy |
| ADX (14) | 16.35 | Neutral |
| ATR (14) | 0.35 | Info |
The near-term technical picture is bearishOverall, the sentiment is BEARISH, with RSI14 at 50, suggesting mixed momentum around the midpoint of the typical range.
Key moving averages show a potential resistance barrier: SMA50 at $6.81 and SMA200 at $8.01. Support is identified at $5.93, with a resistance around $8.70, outlining a defined nearby trading corridor.
The 30-day range for RNAC spans from a low of $4.86 to a high of $9.38, highlighting substantial intra-month volatility within a relatively wide band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.85 | $6.93 | $8.60 | 0% | Neutral | |
| $5.13 | $7.03 | $10.42 | +1% | Neutral | |
| $4.38 | $6.35 | $9.97 | -8% | Neutral | |
| $4.27 | $6.49 | $10.66 | -6% | Neutral | |
| $5.16 | $8.18 | $13.96 | +18% | Neutral | |
| $5.47 | $9.03 | $15.92 | +30% | Bullish | |
| $6.42 | $11.00 | $19.96 | +59% | Bullish | |
| $6.43 | $11.43 | $21.29 | +65% | Bullish | |
| $5.14 | $9.47 | $18.07 | +37% | Bullish | |
| $5.36 | $10.23 | $19.94 | +48% | Bullish | |
| $7.50 | $16.67 | $35.58 | +141% | Bullish | |
| $9.65 | $21.45 | $49.34 | +210% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.85 | $6.93 | $8.28 | +0.00% |
| June 2026 | $6.07 | $7.27 | $8.99 | +4.83% |
| July 2026 | $5.80 | $7.04 | $8.93 | -3.06% |
| August 2026 | $5.60 | $6.89 | $8.89 | -2.17% |
| September 2026 | $5.71 | $7.10 | $9.29 | +2.98% |
| October 2026 | $5.52 | $6.93 | $9.20 | -2.31% |
| November 2026 | $5.07 | $6.41 | $8.61 | -7.49% |
| December 2026 | $4.97 | $6.34 | $8.60 | -1.13% |
Click any year to see its month-by-month RNAC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect RNAC to range from $5.85 to $8.60 through 2026. The $6.93 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The RNAC price prediction for 2027 points to an average of $7.03 (low $5.13, high $10.42) — a potential gain of +1% on today's $6.93. Price action looks broadly range-bound.
In 2028, RNAC is projected to trade between $4.38 and $9.97, averaging $6.35 — a potential decline of -8% from today's $6.93. That is -10% versus the projected 2027 average. A consolidation phase looks the most probable path here.
Cartesian Therapeutics, Inc.'s 2029 outlook centres on $6.49, within a $4.27 to $10.66 range. That is up +2% on the projected 2028 average. That marks a -6% change versus current levels. Price action looks broadly range-bound.
By 2030, RNAC could reach as high as $13.96, with a base case around $8.18 and support toward $5.16 — roughly +18% from $6.93. A consolidation phase looks the most probable path here.
Expect RNAC to range from $5.47 to $15.92 through 2031. The $9.03 average target implies a +30% move from current prices. That is up +10% on the projected 2030 average. Momentum favours further upside here.
The RNAC price prediction for 2032 points to an average of $11.00 (low $6.42, high $19.96) — a potential gain of +59% on today's $6.93. Buyers look set to stay in control over this stretch.
In 2033, RNAC is projected to trade between $6.43 and $21.29, averaging $11.43 — a potential gain of +65% from today's $6.93. That is up +4% on the projected 2032 average. Momentum favours further upside here.
Cartesian Therapeutics, Inc.'s 2034 outlook centres on $9.47, within a $5.14 to $18.07 range. That is -17% versus the projected 2033 average. That marks a +37% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, RNAC could reach as high as $19.94, with a base case around $10.23 and support toward $5.36 — roughly +48% from $6.93. Momentum favours further upside here.
Expect RNAC to range from $7.50 to $35.58 through 2040. The $16.67 average target implies a +141% move from current prices. That is up +63% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The RNAC price prediction for 2050 points to an average of $21.45 (low $9.65, high $49.34) — a potential gain of +210% on today's $6.93. Momentum favours further upside here.
Investing $1,000 in RNAC today (≈ 144.300144 RNAC) could be worth
$3,095.82
+$2,095.82 (+210%) by 2050 · US Dollar
Based on the average projected RNAC price of $21.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RNACwould be worth at today's price.
$1,000 invested in RNAC on May 27, 2025 (≈ 114.02508 RNAC) would be worth
$790.19
-$209.81 (-21.0%) today · 0.79× · US Dollar
Based on a RNAC entry price of $8.77 vs. today's $6.93.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.52 | $1,062.88 | +6.3% |
| 1 month ago | $7.09 | $977.43 | -2.3% |
| 3 months ago | $8.35 | $829.94 | -17.0% |
| 6 months ago | $7.49 | $925.23 | -7.5% |
| 1 year ago | $8.77 | $790.19 | -21.0% |
| All time (5.0y) ago | $134.7 | $51.45 | -94.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RNAC forecast.
Our base-case forecast reaches $14.00 around 2040.
Implied market cap at $14.00: $411.34M
Over the long horizon, the year-by-year forecast shows a shift to a bullish stance beginning in 2031, with 2031 avg at $8.43 and ROI of 24.9%, followed by 2032 avg $10.40 with ROI 54.1% and 2033 avg $10.67 with ROI 58.1%. The 2030s exhibit continued upside, with 2030 avg $7.63 and ROI 13.1%.
In 2040 the forecast shows a strong upturn: avg $15.31 and ROI 126.8%, and the trajectory remains positive into 2050 with avg $19.75 and ROI 192.6%. The sentiment is BULLISH in the later years (2031–2050) as per the forecast. While these figures illustrate meaningful upside, they are estimates and not guarantees, and the path includes periods of lower or negative returns in earlier years (for example, 2028 with min $4.19, avg $6.08, max $9.55 and ROI -10%).
Tap a question to reveal the answer.
Year 2030: min $4.82, avg $7.63, max $13.03; ROI 13.1%; sentiment NEUTRAL.
The forecast shows a mix of outcomes: 2028 min $4.19 avg $6.08 max $9.55 ROI -10% and 2029 min $4.08 avg $6.20 max $10.19 ROI -8.2%, followed by positive upside from 2030 onward (2030 avg $7.63, ROI 13.1%; 2031 avg $8.43, ROI 24.9%; 2040 avg $15.31, ROI 126.8%; 2050 avg $19.75, ROI 192.6%). These are estimates, not guarantees, and should be evaluated in a broader risk context.
The 2040 max is $32.65 and the 2050 max is $45.43, while the 2040 avg is $15.31 and the 2050 avg is $19.75. The forecast allows prices above $20 in the range of the max values, but averages by 2040 and 2050 remain below or around $20 for the mid path.
Current price is $6.75 and market cap is $198.33M.
2031 avg $8.43, ROI 24.9%, sentiment BULLISH; 2032 avg $10.40, ROI 54.1%, sentiment BULLISH; 2033 avg $10.67, ROI 58.1%, sentiment BULLISH.
Cartesian Therapeutics, Inc. Community Discussion
0Share your Cartesian Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.